new drug
PHARMACY

Mylan gets FDA green light for generic Canasa

BY Sandra Levy

The Food and Drug Administration has approved Mylan’s mesalamine rectal suppository, 1000mg.

Mesalamine rectal suppository is the first generic version of Allergan’s Canasa rectal suppository, 1000  mg.

The product is for the treatment of mildly to moderately active ulcerative proctitis.

Mesalamine rectal suppository, 1000 mg had a market value of approximately $263 million for the 12 months ending October 31, 2018, according to IQVIA.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Walgreens, Verily partner on health innovation

BY David Salazar

A new partnership between Walgreens Boots Alliance and a Google sister company is bringing various projects aimed at improving health outcomes to its patients and employees. WBA will be working with Verily, an Alphabet company, on multiple projects under an agreement focused on outcomes for patients with chronic conditions and lowering the cost of care.

“We’re focused on finding innovative ways to deliver better patient care at lower costs, and working with the right healthcare partners to help bring new services and solutions to our patients and customers,” said Stefano Pessina, CEO of Walgreens Boots Alliance. “The continued rise in chronic diseases today can be costly to patients as well as to our healthcare system. Working with Verily, we’ll look at how we can best support integrated and value-based care to meet our patients’ needs, as well as opportunities to address other chronic conditions over time.”

As part of the partnership, Walgreens will be a first-choice retail pharmacy commercialization and development for Verily, and the two companies will collaborate on how to improve access to advanced health tech and solutions — including sensors and software to prevent, manage and diagnose diseases. All of this will be done with the goal of scaling deployment at Walgreens stores.

Out of the gate, the companies are developing a medication adherence pilot project that will deploy devices and other adherence-improvement approaches. Additionally, in partnership with Onduo — Verily’s joint venture with Sanofi — Walgreens will launch a diabetes solution to its employees and their family members with Type 2 diabetes through the employee health plan. Onduo offers tools, coaching and remote access to specialty doctors, all of which can help patients with diabetes manage their condition.

“We are well aligned with Walgreens on the need to develop and bring to market solutions that help people better engage with their health and manage their chronic conditions. This relationship affords us the opportunity to jointly tackle real-world issues that significantly impact the health of individuals and communities,” said Andrew Conrad, chief executive officer, Verily. “Medication adherence, which represents one of the most significant and costly barriers to improving patient outcomes, is an area that I am most excited to work on with a partner like Walgreens.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

AstraZeneca, Merck’s Lynparza is approved by FDA

BY Sandra Levy

AstraZeneca and Merck have received the Food and Drug Administration’s blessing for Lynparza (olaparib) for use as maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated,(gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.

“Women with ovarian cancer are often first diagnosed with advanced disease, which is associated with poor outcomes. In SOLO-1, Lynparza in the first-line maintenance setting reduced the risk of disease progression or death by 70% for patients with BRCAm advanced ovarian cancer. Today’s approval is a critical advancement and brings us closer to our goal of helping these patients achieve long-term remission,” executive vice president, head of the oncology business unit at AstraZeneca Dave Fredrickson said.

Lynparza is the first PARP inhibitor approved in first-line maintenance for BRCAm advanced ovarian cancer.

“The expanded approval of Lynparza based upon the SOLO-1 trial has the potential to change medical practice and reinforces the importance of knowing a woman’s BRCA status at diagnosis. We continue to work in collaboration with AstraZeneca on our overall goal of improving outcomes for patients.” senior vice president and head of global clinical development, chief medical officer Merck Research Laboratories, Roy Baynes said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?